Blog
RSS FeedPosted by Michael Wonder on 26 Jan 2016
NICE issues final guidance recommending 7 drugs for rheumatoid arthritis
26 January 2016 - In final updated guidance published today NICE recommends a number of drugs called biological disease modifying drugs ...
Posted by Michael Wonder on 23 Jan 2016
NICE draft guidance recommends nivolumab for advanced skin cancer
22 January 2016 - The independent Committee decided that a consultation on the draft recommendations was not needed for this appraisal, ...
Posted by Michael Wonder on 28 Dec 2015
NICE issues revised draft guidance on ezetimibe for hypercholesterolaemia
24 December 2015 - NICE is reviewing its guidance on ezetimibe (Ezetrol, MSD) for adults with primary (heterozygous-familial and non-familial) hypercholesterolaemia. ...
Posted by Michael Wonder on 16 Dec 2015
NICE recommends elosulfase alfa (Vimizim) for treatment of very rare life-limiting genetic disorder under managed access agreement
16 December 2015 - In final guidance as part of its Highly Specialised Technologies Programme, NICE has recommended Elosulfase alfa (Vimizin, ...
Posted by Michael Wonder on 16 Dec 2015
NICE issues guidance not recommending apremilast for psoriatic arthritis
16 December 2015 - NICE has published final guidance today which does not recommend apremilast (Otezla, Celgene) for adults with active ...
Posted by Michael Wonder on 16 Dec 2015
Kadcyla price too high for routine NHS funding, says NICE in final guidance
16 December 2015 - NICE has issued its final guidance on the use of Kadcyla (trastuzumab emtansine) as a treatment for ...
Posted by Michael Wonder on 16 Dec 2015
NICE says yes to dry eye disease treatment in final guidance
16 December 2015 - NICE has published final guidance recommending cyclosporin (Ikervis, Santen Pharmaceutical) for treating severe keratitis in adults with ...
Posted by Michael Wonder on 14 Dec 2015
NICE intends to recommend olaparib for ovarian, fallopian tube and peritoneal cancer after company provides more information
11 December 2015 - The draft recommendations say that olaparib should be available for people only if they have had ...
Posted by Michael Wonder on 13 Dec 2015
NICE publishes draft guidance on two prostate cancer treatments
11 December 2015 - NICE has issued draft guidance for enzalutamide and abiraterone acetate as treatment options for prostate cancer. ...
Posted by Michael Wonder on 05 Dec 2015
Benefits of new drug to treat rare inherited bone disorder too uncertain to justify its high cost says NICE in draft guidance
3 December 2015 - NICE has today published draft guidance as part of its highly specialised technologies programme that does not ...
Posted by Michael Wonder on 03 Dec 2015
Alexion's $550,000 bone drug too expensive for Britain
2 December 2015 - A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals ALXN.O that costs more ...
Posted by Michael Wonder on 03 Dec 2015
NICE turns down Alexion's £366K-a-year bone disease drug
3 December 2015 - NHS cost regulators are planning to reject Alexion’s therapy for an ultra-rare bone disorder called paediatric-onset hypophosphatasia, ...
Posted by Michael Wonder on 03 Dec 2015
NICE u-turn on Novartis' multiple myeloma drug
3 December 2015 - The National Institute for Health and Care Excellence is now recommending Novartis’ Farydak as a third-line treatment ...
Posted by Michael Wonder on 25 Nov 2015
NICE publishes final drug recommendations for the treatment of four separate medical conditions
25 November 2015 - Each piece of guidance looked at the cost-effectiveness of a particular drug to treat a specific medical ...
Posted by Michael Wonder on 25 Nov 2015
NICE draft guidance recommends elosulfase alfa (Vimizim) for treatment of very rare life-limiting genetic disorder under managed access agreement
23 November 2015 - In final draft guidance as part of its Highly Specialised Technologies Programme, NICE has provisionally recommended Elosulfase ...